Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
1,800
Employees1,800
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
1,800
Employees1,800

ALKS Key Statistics

Market cap
4.83B
Market cap4.83B
Price-Earnings ratio
14.33
Price-Earnings ratio14.33
Dividend yield
Dividend yield
Average volume
1.78M
Average volume1.78M
High today
$29.66
High today$29.66
Low today
$28.96
Low today$28.96
Open price
$29.66
Open price$29.66
Volume
319.94K
Volume319.94K
52 Week high
$36.45
52 Week high$36.45
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

The current Alkermes(ALKS) stock price is $29.23, with a market capitalization of 4.83B. The stock trades at a price-to-earnings (P/E) ratio of 14.33.

On 2025-12-04, Alkermes(ALKS) stock traded between a low of $28.96 and a high of $29.66. Shares are currently priced at $29.23, which is +0.9% above the low and -1.4% below the high.

The Alkermes(ALKS)'s current trading volume is 319.94K, compared to an average daily volume of 1.78M.

In the last year, Alkermes(ALKS) shares hit a 52-week high of $36.45 and a 52-week low of $25.17.

In the last year, Alkermes(ALKS) shares hit a 52-week high of $36.45 and a 52-week low of $25.17.

ALKS News

Simply Wall St 2d
Should Strong Q3 Results and Raised 2025 Guidance Require Action From Alkermes Investors?

In the third quarter of 2025, Alkermes reported earnings from continuing operations of US$0.49 per share, surpassing expectations as its proprietary products po...

Should Strong Q3 Results and Raised 2025 Guidance Require Action From Alkermes Investors?
Simply Wall St 4d
A Look at Alkermes Valuation Following Q3 Earnings Beat and Raised 2025 Outlook

Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contribute...

A Look at Alkermes Valuation Following Q3 Earnings Beat and Raised 2025 Outlook

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
18.8%
Sell
0%

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.